Theryte is a drug discovery and development company that is committed to bringing revolutionary new cancer treatments to market.

Theryte's new approach targets the processes that normally stabilise the cancer cell, allowing the creation of novel, first-in-class anti-cancer drugs with a unique mechanism of action and efficacy against difficult-to-treat tumours.

Theryte aims to exploit its patented discoveries to: (i) develop the breakthrough technology to select pre-clinical candidates for partnering and licensing; (ii) advance a new family of anticancer targets for further drug development; and (iii) develop biomarkers to predict treatment response.

Company Type
Dr Bill Primrose
Dr Bill Primrose